Cue Biopharma Inc

Research Cue Biopharma Inc (CUE) on Bullrun: market cap USD 99.06M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCUE
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 99.06M
• Financial periodFY2025
• RevenueUSD 27.47M
• Revenue growth195.7%
• Net income-USD 26.60M
• Free cash flow-USD 21.86M

Valuation Snapshot

latest market cap is USD 99.06M.

About Cue Biopharma Inc

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation.

Frequently asked questions

What is Cue Biopharma Inc's market cap?

Cue Biopharma Inc's market capitalization is USD 99.06M.

What does Cue Biopharma Inc do?

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.